EU signs deal with Gilead to supply COVID-19 drug

Portfolio
The European Commission has signed an agreement with Gilead Sciences Inc. for supplies of the company’s antiviral drug remdesivir to combat the coronavirus, EC spokesperson Dana Spinant announced on Wednesday.
Gilead Sciences

The Commission signed a EUR 63 million contract with Gilead for Veklury, the brand name for remdesivir, to be made available to EU countries and the UK starting in early August to provide treatment for 30,000 patients with severe COVID-19 symptoms

Fai distribution of the drug among member states will take place using an allocation key based on the recommendations of the European Centre for Disease Prevention and Control, Spinant said.

The Commission also said it’s preparing a joint procurement for further supplies of the medicine to cover extra needs as of October.

The EU conditionally authorised Gilead’s Veklury drug for treating severe coronavirus patients in July, but nearly all available supplies have already been bought by the United States.

Gilead shares rose 0.6% before market opening on Wednesday and have gained 13.5% this year.

Covr photo: Justin Sullivan/Getty Images

More in Business

otp
August 07, 2020 11:55

Hungary’s OTP posts strong Q2 results

Bank appears to be crisis-resistant

August 07, 2020 10:11

Hungary’s OTP buys 110,000 treasury shares

Programme spending nearly HUF 63 bn this year

Megvan az MFB új vezérigazgatója
August 06, 2020 16:42

Hungarian Development Bank H1 profit jumps

No profit expected in 2020

telekom
August 06, 2020 12:15

Hungary’s Magyar Telekom posts 20% drop in Q2 profit

Management to step up fiber investments

OTP
August 06, 2020 10:22

Hungary’s OTP buys 30,000 treasury shares

Programme spending nears HUF 62 bn this year

mol
August 05, 2020 16:29

Hungary’s Mol Q2 results expected to have been hit hard by coronavirus

Analysts forecast 84% lower EBITDA